바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.72 No.2
Citation Share

A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2012, v.72 no.2, pp.207-211










& (2012). A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine. Tuberculosis & Respiratory Diseases, 72(2), 207-211.
  • Downloaded
  • Viewed
PDF Download

Abstract

Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.

keywords
Hemolytic-Uremic Syndrome, Gemcitabine, Lung Neoplasms

Reference

1.

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.

2.

2. Blackall DP, Marques MB. Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation. Am J Clin Pathol 2004;121 Suppl:S81-8.

3.

3. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60.

4.

4. Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009; 4:209-14.

5.

5. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023-32.

6.

6. Saif MW, Xyla V, Makrilia N, Bliziotis I, Syrigos K. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf 2009;8:257-60.

7.

7. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007;8:634-41.

8.

8. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-46.

9.

9. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis;33:555-62.

10.

10. Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP 2005;6:369-74.

11.

11. Duperray A, Tranqui L, Alix JL, Cordonnier D. Effect of mitomycin C on prostacyclin synthesis by human endothelial cells. Biochem Pharmacol 1988;37:4753-7.

12.

12. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin- based chemotherapy. Oncology 1985;42:296-300.

13.

13. Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999; 74:570-4.

14.

14. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006;108: 1267-79.

15.

15. Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989;64:1017-20.

16.

16. Werner TL, Agarwal N, Carney HM, Rodgers GM. Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol 2007;82:295-8.

17.

17. Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist 2009;14:769-79.

18.

18. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003;14:1072-81.

19.

19. Fakhouri F, Frémeaux-Bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007;3:679-87.

20.

20. Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, et al. Rituximab-based therapy for gemcitabine- induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol 2009;64:177-81.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy